DK2825181T3 - Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom - Google Patents

Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom Download PDF

Info

Publication number
DK2825181T3
DK2825181T3 DK13711116.7T DK13711116T DK2825181T3 DK 2825181 T3 DK2825181 T3 DK 2825181T3 DK 13711116 T DK13711116 T DK 13711116T DK 2825181 T3 DK2825181 T3 DK 2825181T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
carbon particles
liver disease
porous carbon
Prior art date
Application number
DK13711116.7T
Other languages
Danish (da)
English (en)
Inventor
Carol Angela Howell
Sergey Victorovich Mikhalovsky
Susan Rachel Sandeman
Rajiv Jalan
Jane Macnaughtan
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Application granted granted Critical
Publication of DK2825181T3 publication Critical patent/DK2825181T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/15—Nano-sized carbon materials
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/16—Pore diameter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Materials Engineering (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
DK13711116.7T 2012-03-16 2013-03-15 Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom DK2825181T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1204696.7A GB201204696D0 (en) 2012-03-16 2012-03-16 Therapy
PCT/GB2013/050673 WO2013136094A1 (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease

Publications (1)

Publication Number Publication Date
DK2825181T3 true DK2825181T3 (da) 2020-04-14

Family

ID=46052080

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13711116.7T DK2825181T3 (da) 2012-03-16 2013-03-15 Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom

Country Status (16)

Country Link
US (1) US9844568B2 (enExample)
EP (2) EP2825181B1 (enExample)
JP (2) JP6293680B2 (enExample)
KR (2) KR102441934B1 (enExample)
CN (1) CN104363916B (enExample)
AU (1) AU2013234099B2 (enExample)
BR (1) BR112014022810B1 (enExample)
DK (1) DK2825181T3 (enExample)
EA (1) EA038965B1 (enExample)
GB (1) GB201204696D0 (enExample)
IN (1) IN2014DN07637A (enExample)
MY (1) MY169093A (enExample)
NZ (1) NZ631429A (enExample)
SG (1) SG11201405771QA (enExample)
WO (1) WO2013136094A1 (enExample)
ZA (1) ZA201406989B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
ES2727153T3 (es) * 2014-04-17 2019-10-14 Immutrix Therapeutics Inc Composiciones de destoxificación terapéutica y métodos para la preparación y utilización de las mismas
TWI607765B (zh) * 2014-08-27 2017-12-11 Kureha Corp Adsorbents for oral administration, and nephropathy therapeutic agents and liver disease therapeutic agents
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제
EP3476818A1 (en) 2017-10-27 2019-05-01 Heraeus Battery Technology GmbH A process for the preparation of a porous carbon material using an improved carbon source
EP3476817A1 (en) 2017-10-27 2019-05-01 Heraeus Battery Technology GmbH A process for the preparation of a porous carbon material using an improved amphiphilic species
WO2019131209A1 (ja) * 2017-12-27 2019-07-04 株式会社クラレ 活性炭およびその製法
JP7228498B2 (ja) * 2018-10-24 2023-02-24 フタムラ化学株式会社 フェノール樹脂の製造方法
WO2020085282A1 (ja) * 2018-10-24 2020-04-30 フタムラ化学株式会社 フェノール樹脂の製造方法
JP7338993B2 (ja) * 2019-03-06 2023-09-05 株式会社クラレ 多孔質炭素および多孔質炭素の製造方法
JP7061640B2 (ja) * 2019-04-16 2022-04-28 フタムラ化学株式会社 活性炭吸着剤の製造方法
WO2020213559A1 (ja) * 2019-04-16 2020-10-22 フタムラ化学株式会社 活性炭吸着剤の製造方法
JP7563145B2 (ja) * 2019-12-05 2024-10-08 artience株式会社 多孔質炭素及びその製造方法
WO2024261472A1 (en) * 2023-06-20 2024-12-26 Yaqrit Limited Porous carbon particles for use in therapy
KR102971111B1 (ko) 2023-09-05 2026-06-02 한국생산기술연구원 열경화성 에폭시 조성물, 이의 경화물 및 용도
CN121925310A (zh) * 2025-03-28 2026-04-24 大阪燃气化学有限公司 麻醉气体吸附剂、麻醉气体吸附过滤器、吸入麻醉系统以及麻醉气体的去除方法
JP7724390B1 (ja) * 2025-03-28 2025-08-15 大阪ガスケミカル株式会社 麻酔ガス吸着剤、麻酔ガス吸着剤の製造方法、麻酔ガス吸着フィルター、吸入麻酔システム、および、麻酔ガスの除去方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5332637B2 (enExample) * 1973-05-09 1978-09-09
JPS51151693A (en) 1975-06-23 1976-12-27 Eisai Co Ltd Coated bead-like activated carbon for blood purification
JPS5673542A (en) 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
JPS5731864A (en) * 1980-08-04 1982-02-20 Teijin Ltd Oral activated carbon microcapsule
RU2177319C2 (ru) * 1999-03-30 2001-12-27 Российская медицинская академия последипломного образования МЗ РФ Способ лечения гиперэндотоксинемии
GB0019417D0 (en) 2000-08-09 2000-09-27 Mat & Separations Tech Int Ltd Mesoporous carbons
JP3522708B2 (ja) 2001-04-11 2004-04-26 呉羽化学工業株式会社 経口投与用吸着剤
JP4311923B2 (ja) * 2002-10-07 2009-08-12 株式会社クレハ 経口投与用肝疾患治療又は予防剤
EP1407772B9 (en) 2002-10-09 2007-02-21 Kureha Corporation Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases
CA2504517C (en) 2002-11-01 2008-08-12 Kureha Corporation Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP2005089306A (ja) * 2003-09-12 2005-04-07 Ajinomoto Co Inc 炎症性腸疾患治療用の経直腸投与製剤
JP4382629B2 (ja) * 2003-10-22 2009-12-16 株式会社クレハ 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤
KR101135260B1 (ko) * 2003-10-22 2012-04-12 가부시키가이샤 쿠레하 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제
TWI370013B (en) * 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
TWI370012B (en) 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
JP2007045775A (ja) 2005-08-11 2007-02-22 Japan Organo Co Ltd 含水活性炭及びその製造方法
DE102005062160A1 (de) 2005-12-19 2007-06-21 BLüCHER GMBH Aktivkohle für die medizinische Verwendung
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
CA2660883C (en) 2006-10-09 2014-12-09 British American Tobacco (Investments) Limited Carbonising and/or activating carbonaceous material
BRPI0719161A2 (pt) 2006-10-09 2014-02-04 British American Tobacco Co Processos para produzir glóbulos sólidos discretos de material polimérico, para preparar um produto de carbono ativado, e para preparar um produto particulado carbonizado, aparelho para formar glóbulos sólidos discretos de material polimérico, métodos para carbonizar e ativar material carbonáceo, e para preparar carbono ativado, e, forno rotativo.
WO2010138519A2 (en) 2009-05-27 2010-12-02 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres for the treatment of pruritus
GB0921528D0 (en) * 2009-12-09 2010-01-27 Mast Carbon Internat Ltd Carbon and its use in blood cleansing applications
PL2538930T3 (pl) 2010-02-23 2016-11-30 Preparaty do doustnego dostarczania środków adsorbujących do jelita
JP5984352B2 (ja) * 2010-10-12 2016-09-06 フタムラ化学株式会社 経口投与用医薬用吸着剤の製造方法
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy

Also Published As

Publication number Publication date
KR102441934B1 (ko) 2022-09-08
IN2014DN07637A (enExample) 2015-05-15
EP2825181A1 (en) 2015-01-21
EP3650031B1 (en) 2026-07-01
MY169093A (en) 2019-02-18
EP2825181B1 (en) 2020-01-08
EA201491690A1 (ru) 2015-02-27
JP6647570B2 (ja) 2020-02-14
NZ631429A (en) 2016-09-30
EA038965B1 (ru) 2021-11-16
AU2013234099B2 (en) 2017-03-30
SG11201405771QA (en) 2014-10-30
JP6293680B2 (ja) 2018-03-14
KR20200096991A (ko) 2020-08-14
KR102142504B1 (ko) 2020-08-07
BR112014022810B1 (pt) 2021-04-13
AU2013234099A1 (en) 2014-10-02
CN104363916B (zh) 2018-09-25
KR20150002675A (ko) 2015-01-07
WO2013136094A1 (en) 2013-09-19
CN104363916A (zh) 2015-02-18
ZA201406989B (en) 2015-12-23
EP3650031A1 (en) 2020-05-13
EP3650031C0 (en) 2026-07-01
US20150064256A1 (en) 2015-03-05
US9844568B2 (en) 2017-12-19
JP2015516373A (ja) 2015-06-11
JP2018111699A (ja) 2018-07-19
GB201204696D0 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
ZA201406989B (en) Porous carbon particles for use in the treatment or prevention of liver disease
DK2981274T3 (da) Probiotiske stammer til anvendelse ved behandling eller forebyggelse af osteoporose
SI2935303T1 (sl) 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV
EP2809433A4 (en) ELECTRO-SPONSORED POROUS MEDIA
DK2818481T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK3329909T3 (da) Fenfluramin til anvendelse i behandling af dravet syndrom
CO7061071A2 (es) Procesos para la preparación de (s)-1-(3-etoxi-4-metoxifenil)-2-metansulfoniletilamina
DK2819602T3 (da) Kateter til behandling af atrieflagren med enkelt-virkende dobbelt afbøjningsmekanisme
PT3181119T (pt) Composições de alcano semiflourado para utilização no tratamento de queratoconjuntivite seca
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
DK2938740T3 (da) Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK3040336T3 (da) Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
PL3199024T3 (pl) Zastosowanie kompozycji cyklodekstryny i stosowne sposoby
DK2836200T3 (da) Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium
LT3639828T (lt) Deguoninių cholesterolio sulfatų (ocs) panaudojimas ūminio kepenų nepakankamumo gydymui
BR112013024401A2 (pt) métodos e composições para o tratamento do transtorno do déficit de atenção
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
DK2838549T3 (da) Farmaceutisk præparat til forebyggelse eller behandling af ikke-alkoholisk fedtleversygdom
HRP20182046T1 (hr) Uređaj za kuhanje i postupak njegove upotrebe
DK3730136T3 (da) Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom
DK3082831T3 (da) Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol
DK3760707T3 (da) Fibroblaster til anvendelse i behandling af diskusdegeneration
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose